Loading...
KOD logo

Kodiak Sciences Inc.NasdaqGM:KOD Aktienübersicht

Marktkapitalisierung US$2.6b
Aktienkurs
US$39.85
US$63.33
37.1% unterbewertet intrinsischer Abschlag
1Y864.9%
7D-5.7%
Wert des Portfolios
​
Siehe

Kodiak Sciences Inc.

NasdaqGM:KOD Lagerbericht

Marktkapitalisierung: US$2.6b

Kodiak Sciences (KOD) Aktienübersicht

Kodiak Sciences Inc. ist ein biopharmazeutisches Unternehmen im klinischen Stadium, das sich mit der Erforschung, Entwicklung und Vermarktung von Therapeutika zur Behandlung von Netzhauterkrankungen befasst. Mehr Details

KOD grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung3/6
Künftiges Wachstum2/6
Vergangene Leistung0/6
Finanzielle Gesundheit5/6
Dividenden0/6

Belohnungen

88.8% unter unserer Schätzung des beizulegenden Zeitwerts gehandelt

Prognostiziertes jährliches Umsatzwachstum 60.37%

Analysten sind sich einig, dass der Aktienkurs um 58.9%

Risikoanalyse

Hat weniger als 1 Jahr Cash Runway

Erzielt weniger als 1 Million USD an Einnahmen ($0)

Sehr volatiler Aktienkurs in den letzten 3 Monaten im Vergleich zum US -Markt

Derzeit unrentabel und in den nächsten 3 Jahren nicht rentabel zu werden prognostiziert

+ 1 mehr Risiko

KOD Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Kodiak Sciences Inc. Wettbewerber

Preisentwicklung & Leistung

Zusammenfassung der Höchst- und Tiefststände sowie der Veränderungen der Aktienkurse für Kodiak Sciences
Historische Aktienkurse
Aktueller AktienkursUS$39.85
52-Wochen-HochUS$47.84
52-Wochen-TiefUS$2.81
Beta2.32
1 Monat Veränderung-7.56%
3 Monate Veränderung70.88%
1 Jahr Veränderung864.89%
3 Jahre Veränderung656.17%
5 Jahre Veränderung-52.90%
Veränderung seit IPO292.22%

Aktuelle Nachrichten und Updates

Seeking Alpha • Mar 27

Kodiak Sciences: Shares Up On Positive Eye Disease Data - But I Remain On Sidelines

Summary Kodiak Sciences (KOD) surged after positive Phase 3 GLOW2 data for Zenkuda in diabetic retinopathy, demonstrating strong efficacy and risk reduction. KOD plans BLA submissions for Zenkuda across DR, RVO, and Wet AMD, targeting a $15bn market dominated by Roche and Regeneron, with less frequent dosing as a differentiator. Despite robust clinical progress and a 1,300% one-year rally, I maintain a Hold rating due to funding needs, potential dilution, and a congested competitive landscape. Market adoption risks, incumbent strength, and possible near-term fundraising temper enthusiasm, even as pipeline data continues to impress. Read the full article on Seeking Alpha

Recent updates

Seeking Alpha • Mar 27

Kodiak Sciences: Shares Up On Positive Eye Disease Data - But I Remain On Sidelines

Summary Kodiak Sciences (KOD) surged after positive Phase 3 GLOW2 data for Zenkuda in diabetic retinopathy, demonstrating strong efficacy and risk reduction. KOD plans BLA submissions for Zenkuda across DR, RVO, and Wet AMD, targeting a $15bn market dominated by Roche and Regeneron, with less frequent dosing as a differentiator. Despite robust clinical progress and a 1,300% one-year rally, I maintain a Hold rating due to funding needs, potential dilution, and a congested competitive landscape. Market adoption risks, incumbent strength, and possible near-term fundraising temper enthusiasm, even as pipeline data continues to impress. Read the full article on Seeking Alpha
Analyseartikel • Oct 03

We're Keeping An Eye On Kodiak Sciences' (NASDAQ:KOD) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. By way of example, Kodiak...
Seeking Alpha • Feb 24

Kodiak Sciences: Anti-VEGF Could Win Nicely On Retinal Disorders

Summary Kodiak Sciences basically uses a novel biopolymer conjugate platform to develop more durable, next-generation retinal disease therapies. Today, KOD’s pipeline includes Phase 3 candidates for DR, RVO, and wet AMD, targeting an $18 billion TAM by 2028. The main catalyst to watch now is their upcoming pivotal data in 2026 that could lead to FDA approval by 2027. KOD also recently partnered up with Nona Biosciences to enhance its ability to develop multi-target, human monoclonal antibodies. From a valuation perspective, I also think KOD trades near cash value with a strong runway into 2026. So, I believe it’s a decent “Buy” at these levels. Read the full article on Seeking Alpha
Analyseartikel • Dec 13

We're Keeping An Eye On Kodiak Sciences' (NASDAQ:KOD) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Nov 15

Kodiak: Tarcocimab Faces High Barriers To Entry Despite Resurrection (Rating Upgrade)

Summary Kodiak's stock surged 160% since September 2023, despite initial setbacks with tarcocimab in diabetic macular edema studies due to unexpected cataract development. Tarcocimab showed superiority over sham and better tolerability in a Phase 3 diabetic retinopathy trial, prompting Kodiak to resurrect the asset and initiate more pivotal trials. My previous recommendation was "sell" due to high risk and limited upside, but recent positive data and clinical advancements warrant a reassessment. KOD merits a "hold" ahead of key developments in their clinical trials, but this isn't for the faint of heart and works best within a barbell portfolio. Read the full article on Seeking Alpha
Analyseartikel • Aug 02

We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Analyseartikel • Apr 17

We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analyseartikel • Dec 29

We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analyseartikel • Sep 09

We're Keeping An Eye On Kodiak Sciences' (NASDAQ:KOD) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analyseartikel • May 26

Is Kodiak Sciences (NASDAQ:KOD) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analyseartikel • Jan 04

We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analyseartikel • Sep 25

Here's Why We're Watching Kodiak Sciences' (NASDAQ:KOD) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Aug 25

GreenWood Investors - Kodiak Sciences: The Busted Biotech World

Summary Kodiak Sciences busted earlier this year as its first of six pivotal Phase 3 trials on its lead compound, tarcocimab, failed its very poorly designed clinical trial. Subsequent to us taking a stake, Kodiak announced positive data on its most recent registration trial BEACON. Shares have perked up since announcing the BEACON top line data. We are well-aligned with the insiders at the company and the improving fundamentals, we can’t really just “sit this out,” until market conditions improve. The following segment was excerpted from this fund letter. Kodiak Sciences (KOD) A great example of companies that can perform in any environment is busted biotech world. One of the sectors undergoing the most pain in the recent year has been biotech, where we have invested in since 2004. Subsequent to the quarter end, we added a second company to our portfolio, and are actively engaged in researching more busted biotechs. Both our newest, Kodiak Sciences (KOD) and MEI Pharma (MEIP) have important regulatory catalysts in the very near future, and they have ample cash to get them through to the value inflection catalyst points. These are the types of names that can perform in any economic environment. The downside is protected by the cash position, and yes, while those cash positions are being spent on funding drug development, the long runways give us ample time to realize these value inflection milestones. We have been buyers of both companies as the market remains relatively indifferent to the looming regulatory updates. Kodiak Sciences busted earlier this year as its first of six pivotal Phase 3 trials on its lead compound, tarcocimab (formerly KSI-301), failed its very poorly designed clinical trial. The company’s drug will fill a significant unmet medical need, particular for diabetic and elderly patients with macular edema who have given up going to their doctor every 1-2 months to get their eye injected with Regeneron’s EYLEA. Industry research suggests that well over half of patients have chosen deteriorating vision over the inconvenience of getting their eyes injected every 1-2 months. That’s where tarcocimab comes in. In recent trials, even the “failed” trial, it has shown that 60-70% of patients can go five months or longer while maintaining the same significantly improved vision. While there are multiple therapies available for these patients, there are none that have the durability of tarcocimab. Subsequent to us taking a stake, Kodiak announced positive data on its most recent registration trial BEACON. Tarcocimab seeks to disrupt a $13 billion industry, but more importantly, fill an important gap in the macular edema market. In our conversations with doctors actively engaged in research & clinical trials, they are very eager to have a drug that they can dose less frequently. Shares have perked up since announcing the BEACON top line data, but given they still trade below cash levels, they give us a lot of upside as subsequent trials prove out that the drug works. Given the rest of the pivotal trials will read out in the next nine months, we won’t have to wait long until tarcocimab is able to serve the significant unmet medical need, and file for approval with the FDA next year. We also expect a very important update to MEIP’s regulatory strategy which will alleviate market concerns on its own drug’s timeliness to market. While many catalysts depend on a healthy market environment to play out, these do not. They can perform in any economic scenario. Trying to predict with accuracy when the stock will reflect the underlying developments is impossible. But we do know that if you miss the most material upside days of certain stocks, the realized returns are significantly more mediocre. To the extent we are well-aligned with the insiders at the company and the improving fundamentals, we can’t really just “sit this out,” until market conditions improve.
Seeking Alpha • Aug 07

Kodiak Sciences FQ1 2022 Earnings Preview

Kodiak Sciences (NASDAQ:KOD) is scheduled to announce FQ1 earnings results on Monday, August 8th, after market close. The consensus EPS Estimate is -$1.75 Over the last 3 months, EPS estimates have seen 0 upward revisions and 4 downward.
Analyseartikel • May 18

Is Kodiak Sciences (NASDAQ:KOD) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • May 17

Kodiak Sciences: Potential For Comeback After Trial Setback

Results from the BEACON study, which is using KSI-301 for the treatment of patients with retinal vein occlusion, are expected by Q3 of 2022. The global retinal vein occlusion market is estimated to be worth $25.66 billion by 2028. Additional trial readouts using new dosing schedules such as diabetic macular edema, non-proliferative diabetic retinopathy, and treatment naive Wet-AMD are expected in 2023. Kodiak Sciences had $671.7 million in cash as of March 31, 2022, enough cash to fund operations for at least the next 12 months.
Seeking Alpha • Feb 25

Kodiak Sciences: KSI-301 Disappoints

Lead asset KSI-301 is being tested in six pivotal trials in retinal diseases including wet AMD, diabetic macular edema, retinal vein occlusion and non-proliferative diabetic retinopathy. Topline wet AMD data was released and KSI-301 failed to show non-inferiority against standard of care treatment Regeneron’s (REGN) Eylea in improvement in visual acuity. The study did not meet the primary endpoint. While KSI-301 appears safe and effective, it may not become a blockbuster.
Seeking Alpha • Feb 15

Highlighting Kodiak Sciences: A Great Buy Here Ahead Of Phase 3 Wet AMD Data For KSI-301 This Quarter

KSI-301 has shown higher retinal bioavailability and longer half-life than the comparator for this Phase 3 trial, the blockbuster drug Eylea (Aflibercept). Kodiak is attempting to prove non-inferiority in efficacy as shown by BCVA at 1 year vs. Eylea while showing the advantage of less frequent dosing. The first price target is $90 after positive data from the wet AMD Phase 3 trial this quarter or 70% upside potential in the stock (implied move from the options).
Analyseartikel • Jan 24

We're Hopeful That Kodiak Sciences (NASDAQ:KOD) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analyseartikel • Oct 11

Here's Why We're Not Too Worried About Kodiak Sciences' (NASDAQ:KOD) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Jul 19

Kodiak Sciences: Our Current Take On This Mid-Cap Biotech Company

Today, we look at a biotech firm who is developing a portfolio of retina therapeutics built on the company’s antibody biopolymer conjugate platform. Kodiak has late-stage drug candidate targeting wet age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and diabetic retinopathy. A full investment analysis is presented in the paragraphs below.

Aktionärsrenditen

KODUS BiotechsUS Markt
7D-5.7%0.1%2.6%
1Y864.9%35.5%26.2%

Rendite im Vergleich zur Industrie: KOD übertraf die Branche US Biotechs , die im vergangenen Jahr eine Rendite von 35.5 erzielte.

Rendite vs. Markt: KOD übertraf den Markt US, der im vergangenen Jahr eine Rendite von 26.2 erzielte.

Preisvolatilität

Is KOD's price volatile compared to industry and market?
KOD volatility
KOD Average Weekly Movement24.0%
Biotechs Industry Average Movement10.7%
Market Average Movement7.2%
10% most volatile stocks in US Market16.1%
10% least volatile stocks in US Market3.2%

Stabiler Aktienkurs: Der Aktienkurs von KOD war in den letzten 3 Monaten im Vergleich zum US -Markt volatil.

Volatilität im Zeitverlauf: KODDie wöchentliche Volatilität (24%) war im vergangenen Jahr stabil, liegt aber immer noch höher als bei 75 % der US Aktien.

Über das Unternehmen

GegründetMitarbeiterCEOWebsite
2009130Victor Perlrothkodiak.com

Kodiak Sciences Inc. ist ein biopharmazeutisches Unternehmen in der klinischen Phase und beschäftigt sich mit der Erforschung, Entwicklung und Vermarktung von Therapeutika zur Behandlung von Netzhauterkrankungen. Der führende Produktkandidat ist Tarcocimab Tedromer (KSI-301), ein Biopolymer-Antikörper gegen den vaskulären endothelialen Wachstumsfaktor (VEGF), der die klinische Phase-3-Studie zur Behandlung von hochprävalenten Netzhautgefäßerkrankungen abgeschlossen hat und sich in der klinischen Phase-3-Studie zur Behandlung der diabetischen Retinopathie, der feuchten altersbedingten Makuladegeneration (AMD), des Netzhautvenenverschlusses und des diabetischen Makulaödems sowie in der klinischen Phase-2/3-Studie zur Behandlung der feuchten AMD befindet. Zu den Produktkandidaten des Unternehmens in der präklinischen Phase gehören KSI-501, ein Biopolymer-Konjugat gegen Interleukin-6 (IL-6) und VEGF, ein bispezifischer Antikörper zur Behandlung von Netzhautgefäßerkrankungen mit hoher Prävalenz, und KSI-101 (KSI-501P), ein bispezifisches Protein, das auf IL-6 und VEGF abzielt und für Patienten entwickelt wurde, die unter Netzhautflüssigkeit und Entzündungen leiden.

Kodiak Sciences Inc.'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Kodiak Sciences im Vergleich zum Marktanteil des Unternehmens?
KOD grundlegende Statistiken
MarktanteilUS$2.56b
Gewinn(TTM)-US$230.66m
Umsatz(TTM)n/a
0.0x
Kurs-Umsatz-Verhältnis
-10.8x
Kurs-Gewinn-Verhältnis

Ist KOD zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
KOD Gewinn- und Verlustrechnung (TTM)
EinnahmenUS$0
Kosten der EinnahmenUS$0
BruttogewinnUS$0
Sonstige AusgabenUS$230.66m
Gewinn-US$230.66m

Zuletzt gemeldete Gewinne

Mar 31, 2026

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)-3.69
Bruttomarge0.00%
Nettogewinnspanne0.00%
Schulden/Eigenkapital-Verhältnis0%

Wie hat sich KOD auf lange Sicht entwickelt?

Historische Performance und Vergleiche

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2026/05/11 08:28
Aktienkurs zum Tagesende2026/05/11 00:00
Gewinne2026/03/31
Jährliche Einnahmen2025/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Kodiak Sciences Inc. wird von 18 Analysten beobachtet. 4 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
Anita DushyanthBerenberg
Matthew LuchiniBMO Capital Markets Equity Research
Ying HuangBofA Global Research